CBD & EPILEPSY
Last updated 3/14/2020
Response to cannabidiol in epilepsy of infancy
with migrating focal seizures associated with KCNT1 mutations: An
open-label, prospective, interventional study.
Poisson K, Wong M, Lee C, Cilio MR.
Eur J Paediatr Neurol. 2019 Dec 31. pii: S1090-3798(19)30444-1. doi:
10.1016/j.ejpn.2019.12.024. [Epub ahead of print]
PMID:31926846
Efficacy of cannabidiol in subjects with
refractory epilepsy relative to concomitant use of clobazam.
Savage TE, Sourbron J, Bruno PL, Skirvin LA, Wolper ES, Anagnos CJ,
Thiele EA.
Epilepsy Res. 2019 Dec 28;160:106263. doi:
10.1016/j.eplepsyres.2019.106263. [Epub ahead of print]
PMID:31923763
Efficacy and Tolerance of Synthetic Cannabidiol
for Treatment of Drug Resistant Epilepsy.
Klotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs
J.
Front Neurol. 2019 Dec 10;10:1313. doi: 10.3389/fneur.2019.01313.
eCollection 2019.
PMID:31920934
Free PMC Article
The role of cannabinoids in epilepsy treatment: a
critical review of efficacy results from clinical trials.
Nabbout R, Thiele EA.
Epileptic Disord. 2020 Jan 8. doi: 10.1684/epd.2019.1124. [Epub
ahead of print]
PMID:31916540
Cannabis for Pediatric Epilepsy.
Huntsman RJ, Tang-Wai R, Shackelford AE.
J Clin Neurophysiol. 2020 Jan;37(1):2-8. doi:
10.1097/WNP.0000000000000641.
PMID:31895184
Cannabis and Neuropsychiatric Disorders: An
Updated Review.
Chayasirisobhon S.
Acta Neurol Taiwan. 2019 Jun 15;28(2):27-39. Review.
PMID:31867704
Potential role of cannabidiol for seizure control
in a patient with recurrent glioma.
Hsu K, Whitham E, Kichenadasse G.
J Clin Neurosci. 2019 Dec 14. pii: S0967-5868(19)31306-2. doi:
10.1016/j.jocn.2019.11.024. [Epub ahead of print]
PMID:31848037
Exploiting cannabinoid and vanilloid mechanisms
for epilepsy treatment.
Asth L, Iglesias LP, De Oliveira AC, Moraes MFD, Moreira FA.
Epilepsy Behav. 2019 Dec 12:106832. doi:
10.1016/j.yebeh.2019.106832. [Epub ahead of print] Review.
PMID:31839498
The cannabidiol conundrum: potential benefits and
risks of cannabidiol products for children.
Singer L, Tokish H, Park F, Campisi C, Milanaik RL.
Curr Opin Pediatr. 2020 Feb;32(1):198-205. doi:
10.1097/MOP.0000000000000861.
PMID:31833952
Synthetic pharmaceutical grade cannabidiol for
treatment of refractory infantile spasms: A multicenter phase-2
study.
Hussain SA, Dlugos DJ, Cilio MR, Parikh N, Oh A, Sankar R.
Epilepsy Behav. 2020 Jan;102:106826. doi:
10.1016/j.yebeh.2019.106826. Epub 2019 Dec 6.
PMID:31816477
Cannabis Influences the Putative Cytokines-Related
Pathway of Epilepsy among Egyptian Epileptic Patients.
M Taalab Y, Mohammed WF, Helmy MA, Othman AAA, Darwish M, Hassan I,
Abbas M.
Brain Sci. 2019 Nov 20;9(12). pii: E332. doi:
10.3390/brainsci9120332.
PMID:31757102
Free PMC Article Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational
Study of 18 Participants Undergoing Compassionate Use.
Fleury-Teixeira P, Caixeta FV, Ramires da Silva LC, Brasil-Neto JP,
Malcher-Lopes R.
Front Neurol. 2019 Oct 31;10:1145. doi: 10.3389/fneur.2019.01145.
eCollection 2019.
PMID:31736860
Free PMC Article Medicinal cannabis in Latin America: History,
current state of regulation, and the role of the pharmacist in a
new clinical experience with cannabidiol oil.
Cáceres Guido P, Riva N, Calle G, Dell'Orso M, Gatto M, Sberna N,
Schaiquevich P.
J Am Pharm Assoc (2003). 2019 Nov 6. pii: S1544-3191(19)30428-5.
doi: 10.1016/j.japh.2019.09.012. [Epub ahead of print]
PMID:31706799
A new mechanism for cannabidiol in regulating the
one-carbon cycle and methionine levels in Dictyostelium and in
mammalian epilepsy models.
Perry CJ, Finch P, Müller-Taubenberger A, Leung KY, Warren EC,
Damstra-Oddy J, Sharma D, Patra PH, Glyn S, Boberska J, Stewart B,
Baldwin A, Piscitelli F, Harvey RJ, Harwood A, Thompson C, Claus SP,
Greene NDE, McNeish AJ, Williams CM, Whalley BJ, Williams RSB.
Br J Pharmacol. 2019 Nov 6. doi: 10.1111/bph.14892. [Epub ahead of
print]
PMID:31693171
Coadministered cannabidiol and clobazam:
Preclinical evidence for both pharmacodynamic and pharmacokinetic
interactions.
Anderson LL, Absalom NL, Abelev SV, Low IK, Doohan PT, Martin LJ,
Chebib M, McGregor IS, Arnold JC.
Epilepsia. 2019 Nov;60(11):2224-2234. doi: 10.1111/epi.16355. Epub
2019 Oct 17.
PMID:31625159
Free PMC Article Effects of cannabidiol (CBD) in neuropsychiatric
disorders: A review of pre-clinical and clinical findings.
Elsaid S, Kloiber S, Le Foll B.
Prog Mol Biol Transl Sci. 2019;167:25-75. doi:
10.1016/bs.pmbts.2019.06.005. Epub 2019 Aug 28.
PMID:31601406
Beyond THC and Endocannabinoids.
Pacher P, Kogan NM, Mechoulam R.
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:637-659. doi:
10.1146/annurev-pharmtox-010818-021441. Epub 2019 Oct 3.
PMID:31580774
Prospective evaluation of oral cannabis extracts
in children with epilepsy.
Knupp KG, Rice JD, Helmkamp LJ, Galinkin J, Sempio C, Jost K,
Chapman KE.
Seizure. 2019 Nov;72:23-27. doi: 10.1016/j.seizure.2019.09.007. Epub
2019 Sep 16.
PMID:31550641
Cannabidiol Interacts Significantly with
Everolimus-Report of a Patient with Tuberous Sclerosis Complex.
Wiemer-Kruel A, Stiller B, Bast T.
Neuropediatrics. 2019 Dec;50(6):400-403. doi:
10.1055/s-0039-1695786. Epub 2019 Sep 20.
PMID:31539915
Cannabidiol attenuates seizures and EEG
abnormalities in Angelman syndrome model mice.
Gu B, Zhu M, Glass MR, Rougié M, Nikolova VD, Moy SS, Carney PR,
Philpot BD.
J Clin Invest. 2019 Dec 2;129(12):5462-5467. doi: 10.1172/JCI130419.
PMID:31503547
Free Article Position Statement on the Use of Medical Cannabis
for the Treatment of Epilepsy in Canada.
Appendino JP, Boelman C, Brna PM, Burneo JG, Claassen CS, Connolly
MB, De Guzman MVT, Federico P, Floyd D, Huntsman RJ, Javidan M,
Jette N, Jurasek LL, Keezer MR, Lau JC, McCoy B, McLachlan RS, Ng
MC, Nguyen DK, Reid AY, Rho JM, Snead OC, Téllez-Zenteno JF, Wang
L, Zak MM.
Can J Neurol Sci. 2019 Nov;46(6):645-652. doi: 10.1017/cjn.2019.282.
PMID:31466531
Clinicians' Guide to Cannabidiol and
Hemp Oils.
VanDolah HJ, Bauer BA, Mauck KF.
Mayo Clin Proc. 2019 Sep;94(9):1840-1851. doi:
10.1016/j.mayocp.2019.01.003. Epub 2019 Aug 22. Review.
PMID:31447137
Free Article Cannabidiol
reduces seizures following CNS infection with Theiler's murine
encephalomyelitis virus.
Patel DC, Wallis G, Fujinami RS, Wilcox KS, Smith MD.
Epilepsia Open. 2019 Jul 19;4(3):431-442. doi: 10.1002/epi4.12351.
eCollection 2019 Sep.
PMID:31440724
Free PMC Article The safety, tolerability, and effectiveness of
PTL-101, an oral cannabidiol formulation, in pediatric intractable
epilepsy: A phase II, open-label, single-center study.
Mitelpunkt A, Kramer U, Hausman Kedem M, Zilbershot Fink E, Orbach
R, Chernuha V, Fattal-Valevski A, Deutsch L, Heffetz D, Sacks H.
Epilepsy Behav. 2019 Sep;98(Pt A):233-237. doi:
10.1016/j.yebeh.2019.07.007. Epub 2019 Aug 5.
PMID:31394352
Free Article Drug-drug interactions with cannabidiol (CBD)
appear to have no effect on treatment response in an open-label
Expanded Access Program.
Gaston TE, Bebin EM, Cutter GR, Ampah SB, Liu Y, Grayson LP,
Szaflarski JP; UAB CBD Program.
Epilepsy Behav. 2019 Sep;98(Pt A):201-206. doi:
10.1016/j.yebeh.2019.07.008. Epub 2019 Aug 2.
PMID:31382177
Pharmacological and Therapeutic Properties of
Cannabidiol for Epilepsy.
Franco V, Perucca E.
Drugs. 2019 Sep;79(13):1435-1454. doi: 10.1007/s40265-019-01171-4.
Review.
PMID:31372958
Dosage Related Efficacy and Tolerability of
Cannabidiol in Children With Treatment-Resistant Epileptic
Encephalopathy: Preliminary Results of the CARE-E Study.
Huntsman RJ, Tang-Wai R, Alcorn J, Vuong S, Acton B, Corley S,
Laprairie R, Lyon AW, Meier S, Mousseau DD, Newmeyer D,
Prosser-Loose E, Seifert B, Tellez-Zenteno J, Huh L, Leung E, Major
P.
Front Neurol. 2019 Jul 3;10:716. doi: 10.3389/fneur.2019.00716.
eCollection 2019.
PMID:31333569
Free PMC Article Pharmacology of Medical Cannabis.
Amin MR, Ali DW.
Adv Exp Med Biol. 2019;1162:151-165. doi:
10.1007/978-3-030-21737-2_8. Review.
PMID:31332738
Marijuana use among patients with epilepsy at a
tertiary care center.
Kerr A, Walston V, Wong VSS, Kellogg M, Ernst L.
Epilepsy Behav. 2019 Aug;97:144-148. doi:
10.1016/j.yebeh.2019.05.037. Epub 2019 Jun 25.
PMID:31252269
Food effect on pharmacokinetics of cannabidiol
oral capsules in adult patients with refractory epilepsy.
Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski
M, Gramling-Aden M, Leppik IE.
Epilepsia. 2019 Aug;60(8):1586-1592. doi: 10.1111/epi.16093. Epub
2019 Jun 27. Erratum in: Epilepsia. 2019 Sep;60(9):2009.
PMID:31247132
A systematic review of cannabidiol dosing in
clinical populations.
Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O'Sullivan
SE.
Br J Clin Pharmacol. 2019 Sep;85(9):1888-1900. doi:
10.1111/bcp.14038. Epub 2019 Jul 19. Review.
PMID:31222854
Free PMC Article Cognitive functioning following long-term
cannabidiol use in adults with treatment-resistant epilepsy.
Martin RC, Gaston TE, Thompson M, Ampah SB, Cutter G, Bebin EM,
Szaflarski JP.
Epilepsy Behav. 2019 Aug;97:105-110. doi:
10.1016/j.yebeh.2019.04.044. Epub 2019 Jun 18.
PMID:31220785
Cannabidiol inhibits sucrose self-administration
by CB1 and CB2 receptor mechanisms in rodents.
Bi GH, Galaj E, He Y, Xi ZX.
Addict Biol. 2019 Jun 19:e12783. doi: 10.1111/adb.12783. [Epub ahead
of print]
PMID:31215752
Effects of cannabidiol on brivaracetam plasma
levels.
Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J.
Epilepsia. 2019 Jul;60(7):e74-e77. doi: 10.1111/epi.16071. Epub 2019
Jun 18.
PMID:31211851
Purified Cannabidiol for Treatment of Refractory
Epilepsies in Pediatric Patients with Developmental and Epileptic
Encephalopathy.
Pietrafusa N, Ferretti A, Trivisano M, de Palma L, Calabrese C,
Carfì Pavia G, Tondo I, Cappelletti S, Vigevano F, Specchio N.
Paediatr Drugs. 2019 Aug;21(4):283-290. doi:
10.1007/s40272-019-00341-x.
PMID:31179531
Cannabinoids, hippocampal excitability and
efficacy for the treatment of epilepsy.
Yao I, Stein ES, Maggio N.
Pharmacol Ther. 2019 Oct;202:32-39. doi:
10.1016/j.pharmthera.2019.06.002. Epub 2019 Jun 7. Review.
PMID:31176695
Cannabidiol Adverse Effects and Toxicity.
Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò
FP.
Curr Neuropharmacol. 2019;17(10):974-989. doi:
10.2174/1570159X17666190603171901.
PMID:31161980
Medical Marijuana in the Pediatric Population With
Epilepsy-What You Should Know.
Markle M, Nativio DG.
J Pediatr Health Care. 2019 Nov - Dec;33(6):626-632. doi:
10.1016/j.pedhc.2019.03.002. Epub 2019 Jun 1.
PMID:31160106
fMRI study of cannabidiol-induced changes in
attention control in treatment-resistant epilepsy.
Allendorfer JB, Nenert R, Bebin EM, Gaston TE, Grayson LE, Hernando
KA, Houston JT, Hansen B, Szaflarski JP.
Epilepsy Behav. 2019 Jul;96:114-121. doi:
10.1016/j.yebeh.2019.04.008. Epub 2019 May 24.
PMID:31129526
Synthetic, non-intoxicating 8,9-dihydrocannabidiol
for the mitigation of seizures.
Mascal M, Hafezi N, Wang D, Hu Y, Serra G, Dallas ML, Spencer JPE.
Sci Rep. 2019 May 23;9(1):7778. doi: 10.1038/s41598-019-44056-y.
PMID:31123271
Free PMC Article [Use of cannabidiol oil in children].
Wolff D, Reijneveld SA.
Ned Tijdschr Geneeskd. 2019 May 3;163. pii: D3145. Dutch.
PMID:31120211
CBD: A New Hope? Morales P, Reggio PH.
ACS Med Chem Lett. 2019 Apr 29;10(5):694-695. doi:
10.1021/acsmedchemlett.9b00127. eCollection 2019 May 9.
PMID:31097982
Cannabinoid interactions with ion channels and
receptors.
Watkins AR.
Channels (Austin). 2019 Dec;13(1):162-167. doi:
10.1080/19336950.2019.1615824.
PMID:31088312
Free PMC Article Randomized blinded controlled clinical trial to
assess the effect of oral cannabidiol administration in addition
to conventional antiepileptic treatment on seizure frequency in
dogs with intractable idiopathic epilepsy.
McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL.
J Am Vet Med Assoc. 2019 Jun 1;254(11):1301-1308. doi:
10.2460/javma.254.11.1301.
PMID:31067185
Cannabidiol: A Review of Clinical Efficacy and
Safety in Epilepsy.
Samanta D.
Pediatr Neurol. 2019 Jul;96:24-29. doi:
10.1016/j.pediatrneurol.2019.03.014. Epub 2019 Mar 22. Review.
PMID:31053391
Higher cannabidiol plasma levels are associated
with better seizure response following treatment with a
pharmaceutical grade cannabidiol.
Szaflarski JP, Hernando K, Bebin EM, Gaston TE, Grayson LE, Ampah
SB, Moreadith R.
Epilepsy Behav. 2019 Jun;95:131-136. doi:
10.1016/j.yebeh.2019.03.042. Epub 2019 Apr 29.
PMID:31048098
Long-term safety and efficacy of cannabidiol in
children and adults with treatment resistant Lennox-Gastaut
syndrome or Dravet syndrome: Expanded access program results.
Laux LC, Bebin EM, Checketts D, Chez M, Flamini R, Marsh ED, Miller
I, Nichol K, Park Y, Segal E, Seltzer L, Szaflarski JP, Thiele EA,
Weinstock A; CBD EAP study group.
Epilepsy Res. 2019 Aug;154:13-20. doi:
10.1016/j.eplepsyres.2019.03.015. Epub 2019 Mar 25.
PMID:31022635
Free Article Use of Cannabidiol in the Treatment of Epilepsy:
Efficacy and Security in Clinical Trials.
Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E.
Molecules. 2019 Apr 12;24(8). pii: E1459. doi:
10.3390/molecules24081459. Review.
PMID:31013866
Free PMC Article Evidence of a clinically significant drug-drug
interaction between cannabidiol and tacrolimus.
Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR.
Am J Transplant. 2019 Oct;19(10):2944-2948. doi: 10.1111/ajt.15398.
Epub 2019 May 21.
PMID:31012522
Quality of life in adults enrolled in an
open-label study of cannabidiol (CBD) for treatment-resistant
epilepsy.
Gaston TE, Szaflarski M, Hansen B, Bebin EM, Szaflarski JP; UAB CBD
Program.
Epilepsy Behav. 2019 Jun;95:10-17. doi: 10.1016/j.yebeh.2019.03.035.
Epub 2019 Apr 16.
PMID:31003195
Music-Enhanced Analgesia and Antiseizure
Activities in Animal Models of Pain and Epilepsy: Toward
Preclinical Studies Supporting Development of Digital Therapeutics
and Their Combinations With Pharmaceutical Drugs.
Metcalf CS, Huntsman M, Garcia G, Kochanski AK, Chikinda M, Watanabe
E, Underwood T, Vanegas F, Smith MD, White HS, Bulaj G.
Front Neurol. 2019 Mar 27;10:277. doi: 10.3389/fneur.2019.00277.
eCollection 2019.
PMID:30972009
Free PMC Article Don't Fear the Reefer-Evidence Mounts for
Plant-Based Cannabidiol as Treatment for Epilepsy. Perry MS.
Epilepsy Curr. 2019 Mar-Apr;19(2):93-95. doi:
10.1177/1535759719835671.
PMID:30955420
Free PMC Article Single and Synergistic Effects of Cannabidiol and
Δ-9-Tetrahydrocannabinol on Zebrafish Models of
Neuro-Hyperactivity. Samarut É, Nixon J, Kundap UP, Drapeau
P, Ellis LD.
Front Pharmacol. 2019 Mar 20;10:226. doi: 10.3389/fphar.2019.00226.
eCollection 2019.
PMID:30949046
Free PMC Article Cannabidiol as adjunctive treatment of seizures
associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S, Trinka E, Russo E, Striano P, Citraro R, Silvestrini M,
Brigo F.
Drugs Today (Barc). 2019 Mar;55(3):177-196. doi:
10.1358/dot.2019.55.3.2909248. Review.
PMID:30938373
Cannabidiol: Recent advances and new insights for
neuropsychiatric disorders treatment.
Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Pina
SD, Tambaro S, Memo M, Mastinu A.
Life Sci. 2019 May 1;224:120-127. doi: 10.1016/j.lfs.2019.03.053.
Epub 2019 Mar 22. Review.
PMID:30910646
Epidiolex as adjunct therapy for treatment of
refractory epilepsy: a comprehensive review with a focus on
adverse effects.
Sekar K, Pack A.
F1000Res. 2019 Feb 28;8. pii: F1000 Faculty Rev-234. doi:
10.12688/f1000research.16515.1. eCollection 2019. Review.
PMID:30854190
Free PMC Article Cannabidiol in patients with Lennox-Gastaut
syndrome: Interim analysis of an open-label extension study. Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B,
Devinsky O, Checketts D, Roberts C.
Epilepsia. 2019 Mar;60(3):419-428. doi: 10.1111/epi.14670. Epub 2019
Feb 11.
PMID:30740695
Free PMC Article Development of a validated method for the
qualitative and quantitative analysis of cannabinoids in plant
biomass and medicinal cannabis resin extracts obtained by
super-critical fluid extraction.
Elkins AC, Deseo MA, Rochfort S, Ezernieks V, Spangenberg G.
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar
1;1109:76-83. doi: 10.1016/j.jchromb.2019.01.027. Epub 2019 Jan 30.
PMID:30738340
Corrigendum: Potential Clinical Benefits of
CBD-Rich Cannabis Extracts Over Purified CBD in
Treatment-Resistant Epilepsy: Observational Data Meta-analysis.
Pamplona FA, da Silva LR, Coan AC.
Front Neurol. 2019 Jan 10;9:1050. doi: 10.3389/fneur.2018.01050.
eCollection 2018.
PMID:30687209
Free PMC Article Cannabidiol modulates phosphorylated rpS6
signalling in a zebrafish model of Tuberous Sclerosis Complex.
Serra I, Scheldeman C, Bazelot M, Whalley BJ, Dallas ML, de Witte
PAM, Williams CM.
Behav Brain Res. 2019 May 2;363:135-144. doi:
10.1016/j.bbr.2019.01.040. Epub 2019 Jan 23.
PMID:30684511
Cannabinoid therapy in epilepsy.
Billakota S, Devinsky O, Marsh E.
Curr Opin Neurol. 2019 Apr;32(2):220-226. doi:
10.1097/WCO.0000000000000660. Review.
PMID:30676535
Preclinical safety and efficacy of cannabidivarin
for early life seizures.
Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA.
Neuropharmacology. 2019 Apr;148:189-198. doi:
10.1016/j.neuropharm.2019.01.002. Epub 2019 Jan 10.
PMID:30633929
Cannabidiol: A New Hope for Patients With Dravet
or Lennox-Gastaut Syndromes.
Chen JW, Borgelt LM, Blackmer AB.
Ann Pharmacother. 2019 Jun;53(6):603-611. doi:
10.1177/1060028018822124. Epub 2019 Jan 8.
PMID:30616356
Multigenerational consequences of early-life
cannabinoid exposure in zebrafish.
Carty DR, Miller ZS, Thornton C, Pandelides Z, Kutchma ML, Willett
KL.
Toxicol Appl Pharmacol. 2019 Feb 1;364:133-143. doi:
10.1016/j.taap.2018.12.021. Epub 2018 Dec 27.
PMID:30594692
Plants come to mind: phytocannabinoids,
endocannabinoids and the control of seizures.
Farrell JS, Soltesz I.
Addiction. 2019 Aug;114(8):1343-1345. doi: 10.1111/add.14540. Epub
2019 Jan 18. No abstract available.
PMID:30589476
Free PMC Article Cannabidiol reduces seizures and associated
behavioral comorbidities in a range of animal seizure and epilepsy
models. Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn
S, Sandhu H, Jones N, Bazelot M, Williams CM, McNeish AJ.
Epilepsia. 2019 Feb;60(2):303-314. doi: 10.1111/epi.14629. Epub 2018
Dec 26.
PMID:30588604
Free PMC Article Long-term cannabidiol treatment in patients with
Dravet syndrome: An open-label extension trial.
Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S,
Roberts C.
Epilepsia. 2019 Feb;60(2):294-302. doi: 10.1111/epi.14628. Epub 2018
Dec 23.
PMID:30582156
Simultaneous Quantification of 13 Cannabinoids and
Metabolites in Human Plasma by Liquid Chromatography Tandem Mass
Spectrometry in Adult Epilepsy Patients.
Roslawski MJ, Remmel RP, Karanam A, Leppik IE, Marino SE, Birnbaum
AK.
Ther Drug Monit. 2019 Jun;41(3):357-370. doi:
10.1097/FTD.0000000000000583.
PMID:30520828
Emerging drugs for the treatment of Dravet
syndrome.
Brigo F, Striano P, Balagura G, Belcastro V.
Expert Opin Emerg Drugs. 2018 Dec;23(4):261-269. doi:
10.1080/14728214.2018.1552937. Epub 2018 Dec 4. Review.
PMID:30482063
Epilepsy and Cannabis: A Literature Review.
Zaheer S, Kumar D, Khan MT, Giyanwani PR, Kiran F.
Cureus. 2018 Sep 10;10(9):e3278. doi: 10.7759/cureus.3278. Review.
PMID:30443449
Free PMC
Article Cannabis Therapeutics and the Future of Neurology.
Russo EB.
Front Integr Neurosci. 2018 Oct 18;12:51. doi:
10.3389/fnint.2018.00051. eCollection 2018.
PMID:30405366
Free PMC Article Efficacy of cannabinoids in paediatric epilepsy.
Ali S, Scheffer IE, Sadleir LG.
Dev Med Child Neurol. 2019 Jan;61(1):13-18. doi: 10.1111/dmcn.14087.
Epub 2018 Nov 6. Review.
PMID:30402932
Free Article Efficacy and Safety of Cannabidiol in Epilepsy: A
Systematic Review and Meta-Analysis.
Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C,
Silvestrini M.
Drugs. 2018 Nov;78(17):1791-1804. doi: 10.1007/s40265-018-0992-5.
PMID:30390221
Translational Investigation of the Therapeutic
Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA, Guimarães FS, Campos AC, Zuardi AW.
Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009.
eCollection 2018. Review.
PMID:30298064
Free PMC Article Abuse potential assessment of cannabidiol (CBD) in
recreational polydrug users: A randomized, double-blind,
controlled trial.
Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills
C, Etges T, Sommerville K.
Epilepsy Behav. 2018 Nov;88:162-171. doi:
10.1016/j.yebeh.2018.07.027. Epub 2018 Oct 2.
PMID:30286443
Free Article Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy:
Observational Data Meta-analysis.
Pamplona FA, da Silva LR, Coan AC.
Front Neurol. 2018 Sep 12;9:759. doi: 10.3389/fneur.2018.00759.
eCollection 2018. Erratum in: Front Neurol.
2019 Jan 10;9:1050.
PMID:30258398
Free PMC Article Cannabidiol for Treatment of Childhood Epilepsy-A
Cross-Sectional Survey.
Klotz KA, Schulze-Bonhage A, Antonio-Arce VS, Jacobs J.
Front Neurol. 2018 Sep 7;9:731. doi: 10.3389/fneur.2018.00731.
eCollection 2018.
PMID:30258395
Free PMC Article A prospective open-label trial of a CBD/THC
cannabis oil in dravet syndrome.
McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, McDonald
K, Zhang G, Sharma R, Whitney R, Sinopoli K, Snead OC 3rd.
Ann Clin Transl Neurol. 2018 Aug 1;5(9):1077-1088. doi:
10.1002/acn3.621. eCollection 2018 Sep.
PMID:30250864
Free PMC Article Cannabidiol enhances morphine antinociception,
diminishes NMDA-mediated seizures and reduces stroke damage via
the sigma 1 receptor.
RodrÃguez-Muñoz M, Onetti Y, Cortés-Montero E, Garzón J,
Sánchez-Blázquez P.
Mol Brain. 2018 Sep 17;11(1):51. doi: 10.1186/s13041-018-0395-2.
PMID:30223868
Free PMC Article Inhibitory effects of cannabidiol on
voltage-dependent sodium currents.
Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild
SJ.
J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi:
10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
PMID:30219789
Free PMC Article Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE, Szaflarski JP.
Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi:
10.1007/s11910-018-0882-y. Review.
PMID:30194563
Cannabidiol as a suggested candidate for treatment
of autism spectrum disorder.
Poleg S, Golubchik P, Offen D, Weizman A.
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:90-96. doi:
10.1016/j.pnpbp.2018.08.030. Epub 2018 Aug 29. Review.
PMID:30171992
Anticonvulsant and Neuroprotective Effects of
Cannabidiol During the Juvenile Period.
Friedman LK, Wongvravit JP.
J Neuropathol Exp Neurol. 2018 Oct 1;77(10):904-919. doi:
10.1093/jnen/nly069.
PMID:30169677
Efficacy and Safety of Adjunctive Cannabidiol in
Patients with Lennox-Gastaut Syndrome: A Systematic Review and
Meta-Analysis.
Lattanzi S, Brigo F, Cagnetti C, Trinka E, Silvestrini M.
CNS Drugs. 2018 Oct;32(10):905-916. doi: 10.1007/s40263-018-0558-9.
PMID:30132269
Cannabinoid-Based Therapies and Brain Development:
Potential Harmful Effect of Early Modulation of the
Endocannabinoid System.
Schonhofen P, Bristot IJ, Crippa JA, Hallak JEC, Zuardi AW, Parsons
RB, Klamt F.
CNS Drugs. 2018 Aug;32(8):697-712. doi: 10.1007/s40263-018-0550-4.
Review.
PMID:30109642
Cannabidiol improves frequency and severity of
seizures and reduces adverse events in an open-label add-on
prospective study.
Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE,
Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef
LW; UAB CBD Program.
Epilepsy Behav. 2018 Oct;87:131-136. doi:
10.1016/j.yebeh.2018.07.020. Epub 2018 Aug 9.
PMID:30100226
Free Article Open-label use of highly purified CBD
(Epidiolex®) in patients with CDKL5 deficiency disorder and
Aicardi, Dup15q, and Doose syndromes. Devinsky O, Verducci C,
Thiele EA, Laux LC, Patel AD, Filloux F, Szaflarski JP, Wilfong A,
Clark GD, Park YD, Seltzer LE, Bebin EM, Flamini R, Wechsler RT,
Friedman D.
Epilepsy Behav. 2018 Sep;86:131-137. doi:
10.1016/j.yebeh.2018.05.013. Epub 2018 Jul 11.
PMID:30006259
Free Article Long-term safety and treatment effects of
cannabidiol in children and adults with treatment-resistant
epilepsies: Expanded access program results.
Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D,
Beal JC, Laux LC, De Boer LM, Wong MH, Lopez M, Devinsky O, Lyons
PD, Zentil PP, Wechsler R; CBD EAP study group.
Epilepsia. 2018 Aug;59(8):1540-1548. doi: 10.1111/epi.14477. Epub
2018 Jul 12.
PMID:29998598
Free PMC Article The protocol for the Cannabidiol in children with
refractory epileptic encephalopathy (CARE-E) study: a phase 1
dosage escalation study.
Reithmeier D, Tang-Wai R, Seifert B, Lyon AW, Alcorn J, Acton B,
Corley S, Prosser-Loose E, Mousseau DD, Lim HJ, Tellez-Zenteno J,
Huh L, Leung E, Carmant L, Huntsman RJ.
BMC Pediatr. 2018 Jul 7;18(1):221. doi: 10.1186/s12887-018-1191-y.
PMID:29981580
Free PMC Article Affiliate stigma and caregiver burden in
intractable epilepsy.
Hansen B, Szaflarski M, Bebin EM, Szaflarski JP.
Epilepsy Behav. 2018 Aug;85:1-6. doi: 10.1016/j.yebeh.2018.05.028.
Epub 2018 Jun 7.
PMID:29886019
Review of the neurological benefits of
phytocannabinoids.
Maroon J, Bost J.
Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18.
eCollection 2018. Review.
PMID:29770251
Free PMC Article Efficacy of CBD-enriched medical cannabis for
treatment of refractory epilepsy in children and adolescents - An
observational, longitudinal study.
Hausman-Kedem M, Menascu S, Kramer U.
Brain Dev. 2018 Aug;40(7):544-551. doi:
10.1016/j.braindev.2018.03.013. Epub 2018 Apr 16.
PMID:29674131